Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

The CREDENCE trial investigated the efficacy of canagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes and chronic kidney disease. In this randomized, double blind study involving 4401 participants, canagliflozin significantly reduced the risk of the primary composite outcome (end stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death) by 30% compared to placebo (hazard ratio, 0.70; 95% CI, 0.59–0.82; P=0.00001). Key secondary outcomes, including cardiovascular death, myocardial infarction, or stroke, also showed significant reductions. The trial was stopped early due to clear efficacy. Safety profiles were similar between groups, with no increased risk of amputation or fracture. These findings highlight canagliflozin as a promising therapy for renal and cardiovascular protection in high risk patients with type 2 diabetes and nephropathy.

The CREDENCE trial investigated the efficacy of canagliflozin, an SGLT2 inhibitor, in patients with type 2 diabetes and chronic kidney disease. In this randomized, double blind study involving 4401 participants, canagliflozin significantly reduced the risk of the primary composite outcome (end stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death) by 30% compared to placebo (hazard ratio, 0.70; 95% CI, 0.59–0.82; P=0.00001). Key secondary outcomes, including cardiovascular death, myocardial infarction, or stroke, also showed significant reductions. The trial was stopped early due to clear efficacy. Safety profiles were similar between groups, with no increased risk of amputation or fracture. These findings highlight canagliflozin as a promising therapy for renal and cardiovascular protection in high risk patients with type 2 diabetes and nephropathy.